Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
From ESMO Congress 2023:
The use of docetaxel alongside FOLFOX chemotherapy significantly improves outcomes for patients with treatment-naïve, HER2-negative, advanced gastric or gastro-oesophageal junction adenocarcinoma
From ESMO Congress 2023:
Cabozantinib may offer a novel treatment option for patients with extra-pancreatic and pancreatic neuroendocrine tumours
From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer
From ESMO Congress 2023:
Patients with progressive non-muscle-invasive bladder cancer and select FGFR mutations have better recurrence-free survival with oral erdafitinib than an investigator’s choice of intravesical chemotherapy
From ESMO Congress 2023:
The benefits of first-line afatinib for nonsquamous non-small-cell lung cancer extend to patients with uncommon sensitizing EGFR mutations
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
